1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Makers Laboratories Ltd

Makers Laboratories Ltd

187.02
INR
-11.64
(-5.86%)
18.99EPS
Makers Laboratories Ltd
NSE:MAKERSL
(National Stock Exchange of India)

Recent

price

187.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
105.46
121.78
120.1
133.42
126.67
119.83
113.43
109.17
90.98
100.29
138.87
246.96
167.68
175.86
203.42
236.47
252.19
Revenue per Share
6.74
-1.12
4.76
1.16
4.59
4.5
7.22
5.97
4.78
-0.24
-0.67
9.71
-7.9
-10.62
12.7
3.99
5.81
Basic EPS, GAAP
4.71
2.75
0.14
-2.63
-1.36
2.87
-6.52
-3.68
-6.9
-8.51
- -
16.8
-35.8
-9.8
-13.59
17.93
- -
Free Cash Flow per Basic Share
1.21
1.08
- -
- -
- -
1.15
1.15
1.15
1.12
1.15
- -
1.23
1.05
1.07
- -
- -
- -
Dividend per Share
39.88
38.77
43.53
44.69
48.05
59.65
66.47
71.85
81.37
87.07
105.62
121.17
117.28
106.85
119.49
123.59
- -
Book Value per Share
39.86
38.75
43.43
44.5
47.92
59.57
66.44
71.84
81.37
86.93
104.98
120.71
116.06
104.94
117.76
121.92
- -
Tangible Book Value per Share
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
Basic Weighted Avg Shares
540
624
615
684
649
614
581
559
466
514
683
1,266
1,008
1,038
1,200
1,395
1,484
Sales/Revenue/Turnover
10.57
0.22
4.61
1.56
4.68
6.03
7.53
5.81
2.55
2.16
6.6
11.92
-0.72
-3.12
3.5
7.5
9.54
Operating Margin (%)
7
10
10
10
15
13
11
16
15
20
46
40
42
45
48
45
45
Depreciation Expense
35
-6
24
6
24
23
37
31
24
-1
-3
50
-48
-63
75
24
34
Net Income, GAAP
32.69
- -
30.01
49.84
30.82
34.18
30.67
27.83
18.81
149.72
50.14
25.31
- -
- -
18.67
29.5
27.78
Effective Tax Rate (%)
6.39
-0.92
3.97
0.87
3.62
3.76
6.36
5.46
5.25
-0.24
-0.48
3.93
-4.71
-6.04
6.24
1.69
2.3
Profit Margin (%)
16
31
71
104
120
104
99
121
115
44
279
299
357
326
471
529
- -
Working Capital
9
5
- -
- -
- -
- -
- -
- -
60
80
77
46
61
107
34
20
- -
LT Debt
204
199
223
229
246
306
341
368
417
446
866
981
1,097
1,043
1,152
1,225
- -
Total Equity
13.47
- -
7.27
2.08
9.69
7.56
10.64
5.85
1.97
-0.97
2.17
9.95
- -
- -
9
5.83
- -
Return on Invested Capital (%)
14.61
- -
11.35
3.13
10.37
8.96
11.74
9.01
6.16
-0.9
-1.43
-0.46
- -
- -
4.19
-2.1
- -
Return on Capital (%)
19.99
-2.84
11.58
2.63
9.9
8.36
11.45
8.62
6.24
-0.29
-0.67
8.76
-7.38
-9.47
11.22
3.28
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
41
- -
LT Borrowings
- -
10
- -
LT Finance Leases
- -
10
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
- -
- -
- -

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
869
- -
Cash, Cash Equivalents & STI
- -
118
- -
Accounts Receivable, Net
- -
199
- -
Inventories
- -
449
- -
Total Current Liabilities
- -
340
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
41
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.08%
7.39%
6.32%
Free Cash Flow
- -
- -
-231.9%
Net Income, GAAP
-198%
-412.81%
-68.61%
Sales/Revenue/Turnover
11.71%
19.97%
16.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
296
296
277
339
1,200
2026
350
342
357
358
1,395
2027
428
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-1.67
14.94
-0.5
-0.08
12.7
2026
0.74
-0.2
1.59
1.85
3.99
2027
2.55
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Makers Laboratories Limited is an Indian pharmaceutical company specializing in the manufacturing and marketing of pharmaceutical formulations and drug intermediates. Its product portfolio includes tablets, capsules, liquids, injectables, creams, and ointments, with key brands such as Duramol (Paracetamol), Artemak-AB (α-β Arteether), Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (cough remedies), and Exylin (Amoxycillin range). The company operates primarily in India and focuses on branded generics across a wide range of general health therapeutic segments. Founded in 1984 and headquartered in Mumbai, Maharashtra, Makers Laboratories maintains a strong supply chain with significant operations in formulation drugs and drug intermediates. In recent years, Makers Laboratories has undergone significant strategic expansion through the acquisition of a controlling stake in Resonance Specialties Limited in 2020, facilitating its entry into specialty chemicals, active pharmaceutical ingredients (API), and drug intermediates businesses that complement its generic formulations. It has also upgraded and modernized its manufacturing plants, including capacity enhancement and the launch of new ophthalmic products at the Naroda facility in Ahmedabad. The company has continued to report steady growth in sales and operational efficiency, supported by a robust distribution network across India and a strong vendor/supplier base. Makers Laboratories extends its pharmaceutical offerings through segments such as analgesics, anti-infectives, anti-malarials, anti-inflammatory drugs, and respiratory care. Its manufacturing facilities cover solid dosage forms, liquid formulations, injectables, and dermatological products. The company also offers supplementary products like nutritional malt preparations. Recent operational improvements include enhancements in the liquid injectable manufacturing unit and introduction of new product lines aimed at broadening the therapeutic coverage and market presence. Overall, Makers Laboratories Limited is positioned as a comprehensive pharmaceutical manufacturer with diversified product categories spanning branded generics, APIs, and specialty chemicals, supported by recent acquisitions and facility upgrades that underline its strategic intent to strengthen its footprint in the Indian pharmaceutical industry and related chemical sectors.